Polypharmacy Review T. Lewis GP. Six principles of medication review Patients should have a chance to raise questions and highlight problems about their.

Slides:



Advertisements
Similar presentations
Warfarin, Insulin and Digoxin are the most Dangerous drugs in the elderly. Do we believe that?
Advertisements

Implementing NICE guidance
Medication review at the End of Life
Walsall Healthcare NHS Trust Medicines Management.
Table 1: Top five examples of PIP according to the STOPP criteria
Powys-wide, Primary care audit Rhiannon Davies, Powys tHB Medicines Management Team Prescribing of Antipsychotic Medication in Patients with Dementia.
SYMPTOM CONTROL FOR ADVANCED RESPIRATORY DISEASE
Drug Utilization Review (DUR)
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
Preventing admissions in the frail elderly
How to reduce hospital admissions due to high risk drugs Dr Martin Duerden 1.
Safer Medication & Medical Devices Medication Safety & Hospital Admissions Avoidance 30 th June 2015 Dr Ahmed Ameer Medication Safety.
Discharge planning – reducing admissions/re- admissions Jo Clarke, CPPE tutor 1.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
Poster template by ResearchPosters.co.za Independent Pharmacist Prescriber Led Polypharmacy Clinics Pilot in Windsor, Ascot and Maidenhead CCG Melody Chapman,
1 Prescribing Omissions according to START and related hospital admission in geriatric patients O. Dalleur 1, A. Spinewine 2, S. Henrard 3, C. Losseau.
London Respiratory Team Understanding respiratory spend and increasing value: Inhalers and nicotine replacement therapy Responsible Respiratory Prescribing.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
Polypharmacy and preventing hospital admissions
APPLICATION OF THE START-STOPP CRITERIA ON AN ELDERLY POPULATION IN BELGIAN GENERAL PRACTICE: an explorative study J. Landa 1, A. Torsin 1, T. Cornelissen.
Standard 4: Medication Safety Advice Centre Network Meeting Margaret Duguid Pharmaceutical Advisor February 2013.
FHHS ACAT 2012/2013 Audit. A survey of prescribing in the frail elderly with reference to the STOPP criteria.
Measuring and Evaluating Indicators of Appropriate Prescribing in Older Populations Cahir C., Teeling M., Teljeur C., Bennett K., Fahey T. HRB PhD Scholar.
Medication Safety and admissions avoidance: A perspective Steve Williams Consultant Pharmacist in Medicine & Medication Safety Honorary Clinical Lecturer,
Medicines optimisation – a research pharmacist’s perspective Dr David Alldred Senior Lecturer in Pharmacy Practice 23 January 2015Bradford School of Pharmacy1.
Measuring and Evaluating Indicators of Appropriate Prescribing in Older Populations Cahir C., Teeling M., Feely J, Byrne S., Fahey T., Bennett K. Caitriona.
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
Deprescribing with Emphasis on Anticholinergic Burden Dr. Lesley Hannah, Portlethen Medical Centre 2014 I am responsible for providing medical care to.
Using drug use evaluation (DUE) to optimise analgesic prescribing in emergency departments (EDs) Karen Kaye, Susie Welch. NSW Therapeutic Advisory Group*
Community Pharmacy Cheshire & Wirral (CPCW) Helen Murphy Chief Executive Officer Community Pharmacy Cheshire and Wirral.
Community Pharmacy Presentation for Hospital Pharmacists July 2015.
Can the evidence base shape our solutions to polypharmacy?
Medicines Optimisation Polypharmacy and Deprescribing
Pharmacotherapy in older age. Changes in pharmacokinetics and pharmacodynamics Polymorbidity, risk of DRUG-DISEASE interactions Polypharmacy, risk of.
POLYPHARMACY AND MEDICINES OPTIMISATION Professor Tony Avery, University of Nottingham, in collaboration with Dr Martin Duerden Dr Rupert Payne 1.
Pharmacy Technician Pilot : Wendy Bagnall Medicines Management Technician Chris Blunt Practice Manager.
Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.
Pharmacy Service role in supporting informal carers Inverclyde Pharmacy Change Plan Natalie O’Gorman.
East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast NSAIDS – Efficacy and Safety Expert speaker.
Focus on health and care of mothers and infants ChiMat conference, 2009 Professor Mary Renfrew Mother and Infant Research Unit.
Pain Ladder and Opiate Conversion Christopher Haigh Medicines Optimisation Pharmacist Bolton CCG.
NHS Specialist Pharmacy Service Medicine Use Reviews NSAIDs NHS Specialist Pharmacy Service Medicines Use & Safety.
Dr Karl Davis Consultant Geriatrician. Public Health Wales All the frameworks highlighted the following six areas as key priorities (although there is.
Medicines management in the elderly Trudi McIntosh and Kim Munro School of Pharmacy and Life Sciences RGU.
Medication Management in the Older Patient. Older adults are more likely to have an Adverse Drug Reaction More likely to be on 5 or more medications Hazzard,
Care Home Medicine Dr Rhian Simpson Consultant Community Geriatrician Cambridgeshire Community Services.
S Medicine Use Reviews NSAIDs NHS Specialist Pharmacy Services Medicines Use & Safety P S East & South East England Specialist Pharmacy Services East of.
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
Medicines that interact with alcohol See “Guidance on the administration of medicines to inpatients believed to have consumed alcohol ”
East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast Medicine Use Reviews NSAIDs NHS Specialist.
European Community Pharmacy Blueprint A perspective from general practice Professor Tony Avery.
Clear the Clutter: Sage Advice on De-Prescribing Kimberly Wintemute MD CCFP FCFP National Primary Care Co-Lead Annual Clinic Day in Family Medicine, London.
Update on Frailty Assessment in Older Patients with Aortic Stenosis Dr Amy Jones ST5/Clinical Research Fellow Geriatric Medicine.
NHS Specialist Pharmacy Service NSAIDS – efficacy and safety Expert speaker Slide set Key content from the NPC NSAIDS QIPP slides is gratefully acknowledged.
Grant Macdonald.  Appropriate polypharmacy describes treatment where a patient has multiple morbidities, and/or a complex condition, that is being managed.
A Welsh Overview of Pharmacy and Falls Prevention
Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong
PROTON PUMP INHIBITORS (PPI)
CLINICAL GOVERNANCE LEADS MEETING
Audit Opioid use in palliative patients on general hospital wards
Problematic Polypharmacy
8. Causality assessment:
Training package is appropriate
@Improve_Academy #WeStopMeds.
Medicines Optimisation
What’s New in Medication Management: Focus on Older Adults and Caregivers Tuesday, April 30, :00 Noon CDT Mike Varnell, RPh, CSA (214)
Multimorbidity: prevention and management
Primary Care Monitoring of Community Acquired Clostridia difficile
Medicines Optimisation
Clair Huckerby Consultant Pharmacist
Presentation transcript:

Polypharmacy Review T. Lewis GP

Six principles of medication review Patients should have a chance to raise questions and highlight problems about their medicines Medication reviews seek to improve or optimise impact of treatment for individual patients Reviews are undertaken in a systematic way, by competent personnel Any changes resulting from reviews are agreed with the patients Reviews are documented in patients’ notes The impacts of any changes in medication are monitored Task Force on Medicines Partnership and The National Collaborative Medicines Management Services Programme (2002) Room for reviewRoom for review

Polypharmacy ‘ The concurrent use of multiple medication items by an individual.’ Appropriate polypharmacy: defined as prescribing for a complex condition or for multiple conditions in circumstances where medicines use has been optimised and where the medicines are prescribed according to best evidence. Problematic polypharmacy: defined as the prescribing of multiple medications inappropriately, or where the intended benefit of the medication is not realised. The King’s Fund (2013) Polypharmacy and medicines optimisationPolypharmacy and medicines optimisation

Iatrogenic issues Adverse drug reactions account for: 6.5% hospital admissions 4% of bed occupancy Patients admitted have a median hospital stay of 8 days. Drugs most commonly implicated: Low-dose aspirin, diuretics, NSAIDs, warfarin Pirmohamed M et al. (2004). Adverse drug reactions as a cause of admission to hospital: prospective analysis of patients. BMJ 329:15-19

Are you comfortable signing the repeat scripts? Ultimate responsibility for every script lies with whoever signs it.

How do you tackle a polypharmacy review ? T Lewis 2014

STOPP START criteria STOPP (Screening Tool of Older Person's Prescriptions) criteria identifies most commonly prescribed potentially inappropriate medications and START (Screening Tool to Alert doctors to Right Treatment). Gallagher P et al. (2008). STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther. 46:72-83.

STOPP START STOPP e.g. –PPI full therapeutic dose –Aspirin –Duplicate medicines –Benzodiazepines and 1+ fall in last 3 months –Long-term, long-acting benzodiazepines –NSAID long term for mild joint pain osteoarthritis –Long-term opiates or neuroleptics in patients with recurrent falls (1+ fall in last 3 months) Gallagher P et al. (2008). STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther. 46:72-83.

Resources for STOPP START criteria National Prescribing Indicators 2015–2016: Supporting Information for Prescribers

Polypharmacy – Guidance for Prescribing Provides clinicians with a structured process of rationalising patients’ medication, in particular for frail and elderly patients. Includes: Summary charts Medicine-specific advice by BNF chapter Adapted from Abertawe Bro Morgannwg University and Hywel Dda Health Board documents, originally adapted from NHS Highland, and from resources by Emyr Jones, Aneurin Bevan University Health Board.

Polypharmacy – Guidance for Prescribing Polypharmacy – Guidance for Prescribing (Cont.) SUMMARISES KEY CONSIDERATIONS FOR: Drug review process High-risk medications/combinations System-based factors (CV, GI etc) Patients with dementia Anticholinergic load/combinations Frailty Shortened life expectancy Practical guide to stopping medication including transdermal opioids, antidepressants, benzodiazepines Number needed to treat for specific medicines

‘NO TEARS’ Need/indication Open questions Tests/monitoring Evidence/guidelines Adverse effects Risk reduction/prevention Simplification/switches Lewis, T (2004) ‘Using the NO TEARS tool for medication review’ BMJ 329: 434Using the NO TEARS tool for medication review WeMeReC (2005) Bulletin: Medication Review for the 10 minute consultationBulletin: Medication Review for the 10 minute consultation

NO TEARS brief example Medicine Last collected Calcium/Vit D3 bd 562 months ago Betnovate 30 g last month Co-codamol 8/500 mg 2qds prn 200last month Amlodipine 5 mg od 28 last month Gliclazide 80 mg bd 56last month Metformin 500 mg bd 56last month Tramadol 50 mg 2qds prn 100 last month Accu-Chek2 months ago Omeprazole 20 mg od 28last month Glucosamine od 28last month TL 2014

NO TEARS brief example Need and Open Patient’s view of regular medicines? “What do you take each day?” “I realise a lot of people don’t take all their tablets. Do you have any you don’t like?” Calcium taken? PPI still needed? Calcium/Vit D3 bd 56; Betnovate 30 g; amlodipine 5 mg od 28; co-codamol 8/500 mg 2qds prn 200; gliclazide 80 mg bd 56; metformin 500 mg bd 56; tramadol 50 mg 2qds prn 100; Accu-Chek; omeprazole 20 mg od 28; glucosamine od 28 T.L. 2014

NO TEARS brief example Tests Diabetes/hypertension monitoring, osteoarthritis functional impact Evidence Diabetes - consistent with current guidance Osteoarthritis - tramadol? Stop glucosamine Dermatology - steroid on repeat, no emollient Calcium/Vit D3 bd 56; Betnovate 30 g; amlodipine 5 mg od 28; co-codamol 8/500 mg 2qds prn 200; gliclazide 80 mg bd 56; metformin 500 mg bd 56; tramadol 50 mg 2qds prn 100; Accu-Chek; omeprazole 20 mg od 28; glucosamine od 28 T.L. 2014

NO TEARS brief example Adverse Events steroid on repeat Risks co-codamol + tramadol Simplification/synchronisation/switch/stop stop glucosamine, switch glucose testing strips? Calcium/Vit D3 bd 56; Betnovate 30 g; amlodipine 5 mg od 28; co-codamol 8/500 mg 2qds prn 200; gliclazide 80 mg bd 56 metformin 500 mg bd 56; tramadol 50 mg 2qds prn 100; Accu-Chek; omeprazole 20 mg od 28; glucosamine od 28 T.L. 2014

Combine with a basic approach? STOP SORTED SPECIAL T. Lewis 2014

Stop, Sorted, Special Stop The obvious ones –left out when patient lists meds taken –not collected/expired –infrequent requests/low % use –short course completed –shouldn’t be on repeat –hospital letters stated stop –condition resolved T.Lewis 2014

Stop, Sorted, Special Has been assessed and monitored within the last 12 months, e.g. - Chronic disease clinic -Hospital review - and no outstanding concerns T. Lewis 2014

Stopped, Sorted, Special - Priorities Consider medicines recently highlighted: –High-risk medicines –Practice priorities –AWMSG National Prescribing Indicators –Local comparators –MHRA alerts –NICE T. Lewis 2014

Six principles of medication review Patients should have a chance to raise questions and highlight problems about their medicines Medication reviews seek to improve or optimise impact of treatment for individual patients Reviews are undertaken in a systematic way, by competent personnel Any changes resulting from reviews are agreed with the patients Reviews are documented in patients’ notes The impacts of any changes in medication are monitored Task Force on Medicines Partnership and The National Collaborative Medicines Management Services Programme (2002) Room for reviewRoom for review